<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9F1C4EBB-4B03-404A-8803-E054D7D2DC16"><gtr:id>9F1C4EBB-4B03-404A-8803-E054D7D2DC16</gtr:id><gtr:name>Stratified Medicine Scotland Innovation Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E23A7406-001D-414B-BAE2-942602151BCF"><gtr:id>E23A7406-001D-414B-BAE2-942602151BCF</gtr:id><gtr:name>Sistemic Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9F1C4EBB-4B03-404A-8803-E054D7D2DC16"><gtr:id>9F1C4EBB-4B03-404A-8803-E054D7D2DC16</gtr:id><gtr:name>Stratified Medicine Scotland Innovation Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E23A7406-001D-414B-BAE2-942602151BCF"><gtr:id>E23A7406-001D-414B-BAE2-942602151BCF</gtr:id><gtr:name>Sistemic Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/82B8E3C4-22A5-41EE-95C5-FA4955994A7C"><gtr:id>82B8E3C4-22A5-41EE-95C5-FA4955994A7C</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Cumming</gtr:surname><gtr:orcidId>0000-0002-7838-8362</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4D0B2BB2-D7BA-4672-A3C1-925C8077EDA0"><gtr:id>4D0B2BB2-D7BA-4672-A3C1-925C8077EDA0</gtr:id><gtr:firstName>Naveed</gtr:firstName><gtr:surname>Sattar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8143242D-1669-4123-BF46-46B762B57CBA"><gtr:id>8143242D-1669-4123-BF46-46B762B57CBA</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:otherNames>Spencer</gtr:otherNames><gtr:surname>Tobias</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3BAD4EEC-F3A9-4300-908E-25F48DB305BB"><gtr:id>3BAD4EEC-F3A9-4300-908E-25F48DB305BB</gtr:id><gtr:firstName>Sean</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Grimmond</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/333FB934-34B3-42EA-BFC7-A65D2CBB0F12"><gtr:id>333FB934-34B3-42EA-BFC7-A65D2CBB0F12</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Briggs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/93F4EB17-3464-4C27-9B0B-D2F4B8BB7A90"><gtr:id>93F4EB17-3464-4C27-9B0B-D2F4B8BB7A90</gtr:id><gtr:firstName>Jeff</gtr:firstName><gtr:surname>Evans</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7057D7A2-CE96-47F9-885D-C784C9D0892F"><gtr:id>7057D7A2-CE96-47F9-885D-C784C9D0892F</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>McCowan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/34B17AE7-6BEE-4308-BAB0-CB67331A7BDB"><gtr:id>34B17AE7-6BEE-4308-BAB0-CB67331A7BDB</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Victor</gtr:otherNames><gtr:surname>Biankin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/501F6E98-57BB-453B-8214-E98A844944E1"><gtr:id>501F6E98-57BB-453B-8214-E98A844944E1</gtr:id><gtr:firstName>Nicola</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4E3FAA0D-9797-4EAC-84F7-41F37BFD683F"><gtr:id>4E3FAA0D-9797-4EAC-84F7-41F37BFD683F</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McNeish</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1672AEE3-AF3B-4EC8-8E85-935FDDE05A54"><gtr:id>1672AEE3-AF3B-4EC8-8E85-935FDDE05A54</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:surname>Burgoyne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BD6339DF-6706-4458-ACAD-49C246900497"><gtr:id>BD6339DF-6706-4458-ACAD-49C246900497</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>F</gtr:otherNames><gtr:surname>Dominiczak</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/506DAA58-2A21-4153-8306-AF49BEAD9C31"><gtr:id>506DAA58-2A21-4153-8306-AF49BEAD9C31</gtr:id><gtr:firstName>Rhian</gtr:firstName><gtr:surname>Touyz</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ED12213B-F59A-46F6-AE1A-F20804D6CB4B"><gtr:id>ED12213B-F59A-46F6-AE1A-F20804D6CB4B</gtr:id><gtr:firstName>Karin</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Oien</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E0CC83F7-8DAC-4932-8831-4B0DF399BFF0"><gtr:id>E0CC83F7-8DAC-4932-8831-4B0DF399BFF0</gtr:id><gtr:firstName>Muffy</gtr:firstName><gtr:surname>Calder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/961708C6-9E60-4320-A114-532CD16A84CF"><gtr:id>961708C6-9E60-4320-A114-532CD16A84CF</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:surname>Walters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E1B5B39D-0DD7-46D2-94A0-A0FF2BD654B3"><gtr:id>E1B5B39D-0DD7-46D2-94A0-A0FF2BD654B3</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Cooper</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CC9ACEE4-E264-4F1C-90DE-48EBC099AB3A"><gtr:id>CC9ACEE4-E264-4F1C-90DE-48EBC099AB3A</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Barrett</gtr:surname><gtr:orcidId>0000-0001-9447-3519</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FN005813%2F1"><gtr:id>037A04FE-EBA0-4D0A-97FF-66B697A67D97</gtr:id><gtr:title>Glasgow Molecular Pathology (GMP) Node</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N005813/1</gtr:grantReference><gtr:abstractText>The development of treatments for many diseases is slowing, with ever decreasing benefits for patients and dramatic increases in cost. We now understand more about abnormalities in DNA and other molecules which occur in disease. This so-called &amp;quot;molecular pathology&amp;quot; is revealing significant variation in diseases which by standard classifications, for example by a pathologist using a microscope, have been indistinguishable. So, for example, we now know that pancreatic cancer is not just one disease but many different ones, potentially with different treatments. 

Armed with this knowledge and the fact that most new treatments are being developed to target specific molecular abnormalities, it is becoming clear that a tailored, stratified approach to patient selection is required for many aspects of disease management. Molecular pathology could revolutionise medical approaches but at the moment only a few tests are routinely available in the NHS and their implementation from research though to clinical practice is complex. 

The Glasgow Molecular Pathology Node aims to create a dynamic platform that integrates laboratory medicine, including pathology, and informatics disciplines, which handle and analyse the large datasets which emerge from molecular research. In our Node, scientists, pathologists and colleague clinicians will work together to develop and perform new tests, and interpret, deliver and act on results for patient benefit. Glasgow's existing clinical strengths in pathology and molecular diagnostics are delivered from the purpose-built Laboratory Medicine Building within the new &amp;pound;1billion South Glasgow University Hospital campus, which provides services to 52% of the Scottish population. The University of Glasgow's successful restructure in 2010 created multidisciplinary Research Institutes within the College of Medical, Veterinary and Life Sciences which are perfectly positioned to make use of, and support, the proposal. 

Our vision is to transfom the management of cancer and chronic disease by accelerating biomedical research, high quality healthcare provision and economic growth. We will achieve this by working in partnership with world-leading discovery researchers from the College's Institutes for Cardiovascular and Medical Sciences, Cancer Sciences and Infection, Immunity and Inflammation, Health Economics, Bio-engineering and Computer Science, and with industry, to create a multidisciplinary centre of excellence in research and development of molecular diagnostic tests. 

One of the city of Glasgow's mottos is &amp;quot;people make Glasgow&amp;quot;. This was well demonstrated in the recent 2014 Commonwealth Games which were full of &amp;quot;people, place and passion&amp;quot; and our vision is to develop the people, infrastructure and collaborative working practices to enable validation and delivery of high-quality molecular pathology. 

Our strategic focus and objectives are therefore to build capacity in molecular pathology and informatics, through funding for flexible and additional staffing and dedicated high-quality training to develop expertise. This will enable enhanced delivery and development of clinical molecular pathology; and will underpin the parallel development of pipelines for molecular diagnostics validation. 
*We will develop new tests to better diagnose patients and guide their best treatment in cancer, in inflammatory diseases like rheumatoid arthritis, and in cardiovascular and metabolic disease like diabetes, heart disease and stroke. 

Successful realisation of this vision will: 
*Maximise the impact of major recent infrastructure investment; 
*Create the next generation of leaders; 
*Deliver high impact innovation in molecular pathology and complex informatics, with underpinning health economic input, to the
*Benefit of the health and economy of the UK, encompassing NHS care, academic research and UK industry; and 
*Contribute a critical Node to this successful new UK network.</gtr:abstractText><gtr:technicalSummary>Glasgow is ideally positioned to become a Molecular Pathology Node. Our existing clinical strengths in pathology and molecular diagnostics are delivered from the purpose-built Laboratory Medicine Building within our new &amp;pound;1billion South Glasgow University Hospital campus (SGUH), which provides services to 52% of the Scottish population. The University of Glasgow's successful restructure in 2010 created multidisciplinary Research Institutes within the College of Medical, Veterinary and Life Sciences (MVLS) which are perfectly positioned to make use of, and support, the GMP Node proposal. 

Our vision is to transform the management of cancer and chronic disease by accelerating biomedical research, high quality healthcare provision and economic growth. We will achieve this by working in partnership with discovery researchers from the College's Institutes for Cancer Sciences, Infection, Immunity and Inflammation, and Cardiovascular and Medical Sciences, and with industry, to create a multidisciplinary centre of excellence in research and development of molecular diagnostic tests. 

Our strategic focus and objectives are to enhance our capabilities in molecular pathology and informatics, through funding for staffing and high-quality training to further build capacity and expertise. This will enable greater delivery and development of clinical molecular pathology; and will underpin the parallel development of pipelines for molecular diagnostics from discovery through validation and implementation. 

Successful realisation of this vision will: 
* Maximise the impact of major recent infrastructure investment;
* Create the next generation of leaders; 
* Deliver high impact innovation in molecular pathology and complex informatics for the benefit of NHS care, academic research and UK industry; and 
* Contribute a critical Node to this successful new UK network.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit from the programme?
While there has been significant advancement in identifying molecular biomarkers and molecular mechanisms of disease, translation to the clinic has been lagging. Through the node this should be expedited so that benefits in the early prediction, prevention and improved management (including personalized approaches) can be realised. 

Those who would benefit include:

Patients - we will identify and establish new biomarkers with diagnostic potential in cancer, inflammation and cardiovascular diseases. These outputs will a) hold potential in patient treatment stratification strategies; b) facilitate earlier disease diagnosis; and c) ensure more accurate analysis of diseased tissues. The diagnostics developed will be integrated in healthcare practice helping to improve patient treatment strategies and the manage disease through earlier and more accurate diagnosis.

Researchers and academic community- through development of new molecular assays to assist in mechanistic insights of human disease. We will be able to provide unique resources, tools and databases linked to deeply phenotyped patients with relevant diseases. 

Clinicians - through improved prediction, diagnosis and management of patients with relevant disease. Novel validated biomarkers could be incorporated into clinical guidelines and as such impact on clinical care.

NHS and clinical service laboratories - Novel micro-assays of health and disease that will be developed through the Node can be transferred to clinical service laboratories for rapid non-invasive diagnostics that could be used in the clinic.

Industry - will have the opportunity to directly develop, test and validate their platform technologies in an optimal integrated healthcare environment advancing application into practice. Partners will collaborate on multidisciplinary research which will feed on-going developments and enhance their product portfolios. Association with the Node offers SME and Corporate partners the opportunity to further strengthen their reputation internationally, driving longer term economic impact. 

Industry participation in training will help to build capacity creating a workforce in hospital practice and primary care capable of developing, interpreting and applying the results of novel molecular tests. This will support the adoption of standardised procedures and processes, optimising practice nationally and beyond. Downstream it is anticipated that this will influence policy-makers in government agencies and regulators to drive new policy changes in treatment and diagnosis. 

Pharmaceutical and biotech companies - By identifying novel molecular drug targets as a result of deciphering mechanisms of disease at the molecular level (through validated biomarkers), new therapeutic approaches and drugs will be developed. For example, microparticles as a therapeutic delivery system; microRNA and LnRNA as targets; new or repurposed drug development etc. 

Pharma, food industry and regulatory bodies - benefit from the ability to demonstrate potentially positive effects from intervention based on the impact on proteomic biomarkers, which can be employed as surrogates for hard endpoints. Similarly, regulatory agencies can benefit from these surrogates, enabling assessment of benefits, but also potentially harmful effects of novel drugs.

Data management and analysis - Underpinning development is the management of vast datasets. The Node provides the opportunity to develop new informatics and data management systems which integrate across a wide range of diseases and sample types eg tissues and imaging. The close interaction with NHS Greater Glasgow and Clyde Health Board will help to define user functionality and product specification requirements for early adoption within the NHS.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3429808</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stratified Medicine Scotland Innovation Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SMS-IC</gtr:description><gtr:id>D996982A-A2FF-4C96-BD24-66B4FD070A19</gtr:id><gtr:impact>No outputs or outcomes have resulted from this partnership yet.</gtr:impact><gtr:partnerContribution>SMS-IC is supporting PRECISIONPanc through the collection of a wealth of patient-specific data held within the NHS so it can be melded with the genomic data generated for that patient. This data can be used to track the patient journey and has been used to prototype decision support tool for use by the molecular Multi-Disciplinary Team. SMS-IC is co-ordinating delivery of the project together with being the core provider for patient data aggregation and informatics services via the SMS Innovation Platform. SMS-IC have also been providing guidance and expertise to facilitate the accreditation of the Precision Medicine Laboratory at the University of Glasgow.</gtr:partnerContribution><gtr:piContribution>Joint working between the Glasgow Molecular Pathology Node and SMS-IC is facilitating the delivery of PRECISIONPanc. The Node is contributing to the infrastructure required to access patient samples, to provide clinical annotation and to undertake next generation sequencing, including analysis and interpretation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sistemic Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Sistemic Scotland</gtr:description><gtr:id>D7C7DD4B-BEFA-4AE0-AC4C-1F711AA129B1</gtr:id><gtr:impact>No outputs or outcomes have resulted from this partnership yet.</gtr:impact><gtr:partnerContribution>Sistemic have offered their proprietary SistemRNS miRNA profiling technology, databases, algorithms, SOPs and staff expertise.</gtr:partnerContribution><gtr:piContribution>The Node offers Sistemic the opportunity to test the feasibility of diagnostic developments and progress the development of these and their application into clinical practice in fundamental areas of unmet need: cancer, inflammation and cardiovascular diseases. This will enable Sistemic to further validate the diagnostic potential of their miRNA platform. The Node provides access to unprecedented infrastructure, a test-bed offering Sistemic the opportunity to optimise their platform for potential application into a healthcare setting.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>QEUH - Laboratory Medicine Poster day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E16BE449-C4C2-4BC6-97F6-2A773C4BD01E</gtr:id><gtr:impact>The Laboratory Medicine building at the Queen Elizabeth University Hospital hosts an annual poster day which enables students, researchers and clinicians to present research across a range of disciplines. There were 29 posters across a variety of disciplines such as pathology, molecular diagnostics and biochemistry and the award for best poster was presented by the Glasgow Molecular Pathology Node.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Heart Foundation research exhibition Scottish parliament</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>03A6E6C7-D185-430A-AE6B-57ED7B1F6FA2</gtr:id><gtr:impact>Researchers from the cardiovascular workstrand and cardiovascular pathologists contributed to a British Heart Foundation research exhibition at the Scottish parliament. A number of slides with cardiovascular tissue samples were shown under a microscope and also broadcast on to a screen for people to see actual real life images of the various materials.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited plenary talk on the use of technology in genomics education and research, given in October 2016, in Taiwan</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>69965C0E-5B43-4E56-B6BE-CF1EEFF53BA4</gtr:id><gtr:impact>Invited plenary talk given on Sunday 30th October at a conference on Genetics, Reproductive Genetics and Genomics in Changhua, Taiwan in the David Landsborough International Conference Hall. 

This talk was the first of 9 plenary talks at the symposium and it concerned the use of technology to enrich genomics education and research. It was delivered within the session entitled Genetics, Medicine and Biology.

Several professionals spoke to me afterwards to request further information, including a professor &amp;amp; senior consultant of the Karolinska Institute, Stockholm (and ex-president of the Swedish Society of Medical Genetics).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (Oct. 2016) re the Training Workstrand of the Glasgow Molecular Pathology Node at the Node's inaugural symposium at the Glasgow Hilton Grosvenor Hotel.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E9303344-D118-4234-8EEF-97B23E0B66ED</gtr:id><gtr:impact>The inaugural annual symposium of the University of Glasgow MRC Molecular Pathology Node took place on Monday 24 October at the Glasgow Hilton Grosvenor Hotel. It featured talks from Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Professor Dame Anna Dominiczak, as well as from the Director of the MRC Molecular Pathology Node, Dr Karin Oien.

The symposium also featured contributions from Dr Desmond Walsh, Head of Populations and Systems Medicine Board and Lead of Stratified Medicine at the MRC and also David Sibbald, the Executive Chairman of Aridhia.

There were approximately 150 delegates registered for the event, comprising academia, NHS and industry partners. Delegates also included representatives from official partners of the Node.

Importantly, the symposium highlighted the importance of a collaborative approach to precision medicine and it generated significant further interest from additional partners.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Metabolomics Masterclass at the University of Cape Town (S. Africa)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C07DFCF5-2B22-4C9C-A7D4-D40BD979A07A</gtr:id><gtr:impact>Metabolomics workshop in South Africa. I was invited to teach the section on NMR metabolomics and to demo the PicoSpin, a 45 MHz bench-top NMR spectrometer. I also included a hands-on data analysis activity using Chenomx NMR profiling software. The reception was very enthusiastic and we have been invited back next year. Attendees were working on a variety of metabolomics projects, including HIV and tuberculosis.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Molecular Pathology Node Launch event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>960A6837-7EC6-409A-A230-ACACB03C367A</gtr:id><gtr:impact>The Glasgow Molecular Pathology Node launch event presented the Node infrastructure, research and outputs to academics, NHSGG&amp;amp;C, industry and the Node network. Opportunities for engagement with the Node were also highlighted. Approximately 100 people attended the event and a number of potential parternship opportunities were identified with industry. These opportunities are currently being progressed.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Metabolomics Workshop University of Pretoria (South Africa) 2017</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>408F6F7D-403E-406F-AC91-C8799D517E54</gtr:id><gtr:impact>Metabolomics workshop in South Africa. I was invited to teach the section on NMR metabolomics and to demo the PicoSpin, a 45 MHz bench-top NMR spectrometer. I also included a hands-on data analysis activity using Chenomx NMR profiling software. The reception was very enthusiastic and we have been invited back next year.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Molecular Pathology Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A858BC6E-1650-4A6B-B1E6-36DF15AB7EDB</gtr:id><gtr:impact>Karin Oien presented on the Molecular Pathology Nodes to demonstrate how clinicians, academics and industry are working together to build capacity in molecular pathology to maximise the potential patient and economic benefits of stratified medicine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Explorathon - European Researchers Week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0587C265-DA17-4B34-86A6-18457AA24CF5</gtr:id><gtr:impact>The Molecular Pathology Node organised a number of activities to introduce pathology, molecular pathology, stratified medicine and genetics to the public. This event raised awareness of the Node and gave the public the opportunity to learn about what pathologists do to understand causes, mechanisms and effects of diseases. This event highlighted the fact that pathology applies to the living and that pathologists make a huge contribution to the care of living patients. Additionally this event introduced the public to personalised or stratified medicine and allowed them to understand that not everyone who is classified with the same disease will necessarily experience the same rate of disease progression or respond equally well to drugs.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>East Midlands Breathomics Molecular Pathology Node Annual General Assembly</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B22880D-8F14-4305-BF1C-3F644A9C5840</gtr:id><gtr:impact>not sure what to write here</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NHS Research Scotland (NRS) Annual Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D5155330-BF15-499E-B35B-1D2F811661DC</gtr:id><gtr:impact>The Glasgow Molecular Pathology Node set up an exhibition stand at the NHS Research Scotland (NRS) Annual Conference, Scotland's leading clinical research conference, that brings together almost 500 delegates across NHS, academia, industry and third sector. Representatives from the Node engaged in discussions with clinicians, researchers, academics and representatives from industry to raise awareness of the Node and its objectives.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Improving the focus of precision medicine: The role of health technology assessment</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>69497FC8-421C-44A9-B255-9430007ADA09</gtr:id><gtr:impact>Approximately 100 people attended a workshop that considered issues related to the successful development of precision medicine technologies; the potential role of health technology assessment analysis and thinking in the selection of candidate technologies and the design of studies that will provide compelling evidence. The audience were introduced to the Glasgow Molecular Pathology Node and the role of health technology assessment across the Node disease-based workstreams to prioritise promising biomarkers and provide a framework for commercial development.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trainer at the EMBO EBI Practical Course on Metabolomics Informatics for Life Scientists in Cambridge</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA602288-C8D3-42EE-8F09-805D21586052</gtr:id><gtr:impact>PhD students and postdoctoral researchers from across Europe apply to attend and 30 out of 150 applicants are selected. I was invited to teach the NMR spectroscopy psrt of this course. I met other researchers from prestigious metabolomics laboratories and have discussed potential projects with them for collaboration in the future. I have been invited to attend next year.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://www.ebi.ac.uk/training/events/2017/embo-practical-course-metabolomics-bioinformatics-life-scientists-3</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NHS Research Scotland (NRS) Annual Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>476634E5-702F-4DA3-9616-B75BDEDAC394</gtr:id><gtr:impact>The Node workstrand leads for Cancer (Professor Andrew Biankin) and Inflammation (Professor Iain McInnes) presented as part of the Precision Medicine session. These presentations updated on the Scottish Ecosystem for Precision Medicine and demonstrates Scotland's strengths in coordinating clinical, laboratory and informatics resources to deliver the right drug for the right patient at the right time.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MMPathIC industry forum</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DBC9B47F-0701-49CE-8CD7-7DB66C4A659F</gtr:id><gtr:impact>Representatives from the Glasgow Molecular Pathology Node participated in this forum which was aimed at helping to help define a roadmap to market for novel diagnostics and tests through a two-way dialogue between academics and industry.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NHSGGC Medical Genetics</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>012C7761-F49F-4DA0-B486-3ECD6D6D9387</gtr:id><gtr:impact>This presentation higlighted the Molecular Pathology Node and the training opportunities available through the Node, in particular the Masters in Molecular Pathology. Following this presentation 5 scientists from this department applied for and were accepted into the course.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Confederation of Cancer Biobanks conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5449EBF0-85EB-49F5-A480-DD7519C5A899</gtr:id><gtr:impact>Approximately 120 people from across the UK attended a conference titled 'Working together: Collaboration in the cancer biobanking landscape'. The meeting was aimed at maximising opportunities in biobanking and included a presentation from the Node cancer workstrand lead (Professor Andrew Biankin) on the Scottish Genomes Partnership discussing challenges and opportunities for biobanking.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Pathology Week - public engagement event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C896866D-0A7C-44FD-8C95-188EAA035D6D</gtr:id><gtr:impact>Pathologists, geneticists, clinical and biomedical scientists from the Glasgow Molecular Pathology Node set up an booth with a number of interactive activities in the main atrium of the Queen Elizabeth University Hospital. The Node representatives described the roles of pathologists and scientists, the pathway of tissue from biopsy to diagnosis, different pathological tests and the work of the Glasgow Molecular Pathology Node. Our visitors learnt about the importance of genes in cancer and its treatment and, with an interactive bead game, had a go at 'making' complementary DNA by hand and found that it's hard to do accurately and quickly! Feedback showed that patients were interested in the differences in genes and relating these to their own illnesses, and hospital staff were fascinated by molecular pathology and its progress.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to discovery: Industry engagement fund</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MC_PC_16073</gtr:fundingRef><gtr:id>89052097-FA8E-4465-9B6A-97673D6A9A15</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in concept</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>81184F57-2088-4507-A9A3-4B2A432818B6</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Glasgow University MVLS EPSRC Centre for Doctoral Training Student - CDT funded studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>E4E33542-76D4-40B1-8169-E5B813ACEB71</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Masters in Molecular Pathology</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>C95D86D2-7201-4DD1-881A-A0286AAE15B3</gtr:id><gtr:impact>Seventeen students, from the West of Scotland, are currently enrolled in the Masters in Molecular Pathology; 12 trainee pathologists and 5 clinical/biomedical scientists.The multi-disciplinary training, which includes pathology, genetics and exposure to other laboratory medicine specialities, provided as part of the Masters in Molecular Pathology is developing a workforce with appropriate expertise to develop, undertake, interpret and apply the results of novel diagnostics. This is leading to enhanced capacity and expertise which will result in improvements in clinical service delivery.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Additional capacity and expertise</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>CFC72AD7-21B0-42F4-A600-181D893EBC79</gtr:id><gtr:impact>NHSGGC genetics is a nationally recognised and funded training centre for pre-registration clinical scientists. The Node has funded 2 trainees to undertake a model scientist trainig programme for molecular pathology. These posts epitomise development of capacity and expertise. Additionally, for existing consultant pathologists, buy-out of individual four-hour sessions provides dedicated time, aiming to increase expertise in molecular pathology through training; and to train others in pathology, especially scientific staff in Genetics. Together this staffing is enhancing and expanding multi-disciplinary working for development and delivery of molecular pathology.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>This transcriptomic profile will be used to to guide treatment stratification in a subsequent proof-of-concept study and also possible experimental medicine or therapeutic proof-of-concept studies.</gtr:description><gtr:id>9A845ECE-7F7D-43BC-B082-91E8C09FC1AD</gtr:id><gtr:impact>n/a this product is currently under development</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>RNAseq panel (NIMA)</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The technology being developed is a point of care device that will allow simultaneous assessment of numerous metabolites on a single chip device.</gtr:description><gtr:id>BA01BF4C-BF3B-4275-A1BB-41C40787E899</gtr:id><gtr:impact>n/a product currently under development</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Point of care device for assessing risk</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Drug non-adherence, particularly anti-hypertensives, is a significant health issue. An objective test for drug adherence to identify and manage non-adherent individuals is urgently needed. Current methods (questionnaires, pill-counts, and targeted LC-MS/MS) have considerable limitations. A robust drug screening method that addresses all these limitations is a priority. We have demonstrated the proof-of-concept of a novel screening method that allows accurate detection of drugs and their metabolites in patient spot urine samples.</gtr:description><gtr:id>22751B11-05A0-4DFA-92F1-8029C3A24F1C</gtr:id><gtr:impact>n/a product currently under development</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>A novel technique to simultaneously detect drugs, drug metabolites, and endogenous urinary metabolites of patients taking antihypertensive drugs (drugomics)</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Workflows have been established for a target enrichment NGS panel.</gtr:description><gtr:id>C4498D73-0CEE-4B62-A8A6-53D94D1A84B0</gtr:id><gtr:impact>n/a as the product is currently under development</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Panel based diagnostic assay (cancer)</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A patent application is currently being prepared for this product and therefore it is not possible to disclose any information.</gtr:description><gtr:id>542463B8-D3A3-45F5-826B-FDFB560F8AFB</gtr:id><gtr:impact>n/a as the product is still in development</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Targeted RNAseq panel (RA)</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E1958B5-1114-4E4F-BD63-AA2EE0DB489F"><gtr:id>6E1958B5-1114-4E4F-BD63-AA2EE0DB489F</gtr:id><gtr:title>An Integrated Circuit for Chip-Based Analysis of Enzyme Kinetics and Metabolite Quantification.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on biomedical circuits and systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/520a61d22d374b1c6013fe01c8702b84"><gtr:id>520a61d22d374b1c6013fe01c8702b84</gtr:id><gtr:otherNames>Cheah BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-4545</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D460CBF-E916-4D46-9F15-5F4A4801D937"><gtr:id>0D460CBF-E916-4D46-9F15-5F4A4801D937</gtr:id><gtr:title>Genomic analyses identify molecular subtypes of pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55bfe0f26ee0d6f0a86e4c711982bed3"><gtr:id>55bfe0f26ee0d6f0a86e4c711982bed3</gtr:id><gtr:otherNames>Bailey P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/613593EE-F25F-45E7-BE35-B9A49EE2AE81"><gtr:id>613593EE-F25F-45E7-BE35-B9A49EE2AE81</gtr:id><gtr:title>Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c6f162b78e4bd8e25329b066f2b65d17"><gtr:id>c6f162b78e4bd8e25329b066f2b65d17</gtr:id><gtr:otherNames>Maclay JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1FF9077C-5A01-47EA-AC4B-1395E3E3C168"><gtr:id>1FF9077C-5A01-47EA-AC4B-1395E3E3C168</gtr:id><gtr:title>Consensus on precision medicine for metastatic cancers: a report from the MAP conference.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5f89bc266f10341c365606e24326bd0"><gtr:id>e5f89bc266f10341c365606e24326bd0</gtr:id><gtr:otherNames>Swanton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4C7FF81-7FC3-445C-9112-8001907804AF"><gtr:id>C4C7FF81-7FC3-445C-9112-8001907804AF</gtr:id><gtr:title>GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/afb7f115f3e8c05db2e585d730d02614"><gtr:id>afb7f115f3e8c05db2e585d730d02614</gtr:id><gtr:otherNames>Martinelli P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70CF8E48-006D-428B-B412-B7C48ED169FD"><gtr:id>70CF8E48-006D-428B-B412-B7C48ED169FD</gtr:id><gtr:title>Pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8830ba3ab37cc382a0fbf2e5bcbb8faf"><gtr:id>8830ba3ab37cc382a0fbf2e5bcbb8faf</gtr:id><gtr:otherNames>Kleeff J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DCEC79A2-9448-4DF1-A02C-F13450B8CD8F"><gtr:id>DCEC79A2-9448-4DF1-A02C-F13450B8CD8F</gtr:id><gtr:title>Erratum to: Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation</gtr:title><gtr:parentPublicationTitle>Metabolomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c9140d30cb564ad0f1ee0f6f44aa3b1"><gtr:id>0c9140d30cb564ad0f1ee0f6f44aa3b1</gtr:id><gtr:otherNames>van der Hooft J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A7AE010F-D2D6-45FF-871B-8812CF82F34B"><gtr:id>A7AE010F-D2D6-45FF-871B-8812CF82F34B</gtr:id><gtr:title>Genomics and Precision Medicine for Clinicians and Scientists in Hypertension.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/02a608d7e82607c4a8869c13ef574b11"><gtr:id>02a608d7e82607c4a8869c13ef574b11</gtr:id><gtr:otherNames>Dominiczak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FAA76A0-A033-4E8A-9B9D-BC559E5ABF30"><gtr:id>6FAA76A0-A033-4E8A-9B9D-BC559E5ABF30</gtr:id><gtr:title>Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3338305b53006620bdd5390546872d7e"><gtr:id>3338305b53006620bdd5390546872d7e</gtr:id><gtr:otherNames>Babic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C488B659-D965-4874-B00F-F324F0069816"><gtr:id>C488B659-D965-4874-B00F-F324F0069816</gtr:id><gtr:title>Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: Additive value of N-terminal pro-B-type natriuretic peptide.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b4373d12eae2ff4573381f3eb332a2f"><gtr:id>6b4373d12eae2ff4573381f3eb332a2f</gtr:id><gtr:otherNames>Poortvliet RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E20681AB-C200-4D27-BAB6-4D56EF98D5AB"><gtr:id>E20681AB-C200-4D27-BAB6-4D56EF98D5AB</gtr:id><gtr:title>Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c9cd50a1b45b096272f4aef8052cd476"><gtr:id>c9cd50a1b45b096272f4aef8052cd476</gtr:id><gtr:otherNames>Johnatty SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C282F16-D93E-4815-9B61-FD52611AEFEC"><gtr:id>8C282F16-D93E-4815-9B61-FD52611AEFEC</gtr:id><gtr:title>Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c483f77fdb6c5c8781a85ec5eda8bc0"><gtr:id>6c483f77fdb6c5c8781a85ec5eda8bc0</gtr:id><gtr:otherNames>Salvi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B293B35-680E-42FA-A511-B4C573656FC1"><gtr:id>4B293B35-680E-42FA-A511-B4C573656FC1</gtr:id><gtr:title>Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb69f5c0e0bc3dd36b02308b4d28210d"><gtr:id>cb69f5c0e0bc3dd36b02308b4d28210d</gtr:id><gtr:otherNames>Sattar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C22DD171-C4F3-4F31-B87D-0803703F144A"><gtr:id>C22DD171-C4F3-4F31-B87D-0803703F144A</gtr:id><gtr:title>Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e724be049eb36843b02b64126be3760"><gtr:id>4e724be049eb36843b02b64126be3760</gtr:id><gtr:otherNames>Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BA06512-74D6-47CB-BAB5-5B14C0EBFE0F"><gtr:id>0BA06512-74D6-47CB-BAB5-5B14C0EBFE0F</gtr:id><gtr:title>BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ab3771c43210e30cf389ecaea141cd1"><gtr:id>8ab3771c43210e30cf389ecaea141cd1</gtr:id><gtr:otherNames>Meeks HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BE62151-4CEF-4DD2-859F-FBEEB4387871"><gtr:id>5BE62151-4CEF-4DD2-859F-FBEEB4387871</gtr:id><gtr:title>SY 03-1 GENETIC BASIS OF BLOOD PRESSURE AND HYPERTENSION.</gtr:title><gtr:parentPublicationTitle>Journal of hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/02a608d7e82607c4a8869c13ef574b11"><gtr:id>02a608d7e82607c4a8869c13ef574b11</gtr:id><gtr:otherNames>Dominiczak A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96A89C13-DC8F-4F41-9553-C190E6556810"><gtr:id>96A89C13-DC8F-4F41-9553-C190E6556810</gtr:id><gtr:title>Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2539ac88ba377717461068812c27db4f"><gtr:id>2539ac88ba377717461068812c27db4f</gtr:id><gtr:otherNames>Hoogendoorn M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39061FFD-5D48-4073-8184-7C7BC4B3D194"><gtr:id>39061FFD-5D48-4073-8184-7C7BC4B3D194</gtr:id><gtr:title>Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/47021f183ffb28ee647717b052819372"><gtr:id>47021f183ffb28ee647717b052819372</gtr:id><gtr:otherNames>McNeish IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E92F21E-8B79-4B6B-BF7E-13910EC40FA2"><gtr:id>8E92F21E-8B79-4B6B-BF7E-13910EC40FA2</gtr:id><gtr:title>Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42f39d47676cd40bdba631c0a15cb6ff"><gtr:id>42f39d47676cd40bdba631c0a15cb6ff</gtr:id><gtr:otherNames>Porter D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6953A741-7D7F-4638-8CC8-8F6100A166C7"><gtr:id>6953A741-7D7F-4638-8CC8-8F6100A166C7</gtr:id><gtr:title>DNA-directed spatial assembly of photosynthetic light-harvesting proteins.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a493cc3c04e769e5b9dab9d2da82f06d"><gtr:id>a493cc3c04e769e5b9dab9d2da82f06d</gtr:id><gtr:otherNames>Henry SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DCECD8E1-9361-45A1-A8F4-DD7E6A7F48B5"><gtr:id>DCECD8E1-9361-45A1-A8F4-DD7E6A7F48B5</gtr:id><gtr:title>The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f460767649781454eba53de21a508d00"><gtr:id>f460767649781454eba53de21a508d00</gtr:id><gtr:otherNames>Ehret GB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/47B2FEB4-B3BF-43D8-87B8-C236E4F31091"><gtr:id>47B2FEB4-B3BF-43D8-87B8-C236E4F31091</gtr:id><gtr:title>Timing, rates and spectra of human germline mutation.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a77de7807187e482f8939da4314cf4b"><gtr:id>4a77de7807187e482f8939da4314cf4b</gtr:id><gtr:otherNames>Rahbari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6F02C45-258E-4F32-A3C0-8A6C9421531A"><gtr:id>E6F02C45-258E-4F32-A3C0-8A6C9421531A</gtr:id><gtr:title>A Colorimetric CMOS-Based Platform for Rapid Total Serum Cholesterol Quantification</gtr:title><gtr:parentPublicationTitle>IEEE Sensors Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/baaf9da108a9b0e8e02074d0db3f3057"><gtr:id>baaf9da108a9b0e8e02074d0db3f3057</gtr:id><gtr:otherNames>Al-Rawhani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEE783E2-90AA-4F29-9D51-4FD0B1ACD63A"><gtr:id>DEE783E2-90AA-4F29-9D51-4FD0B1ACD63A</gtr:id><gtr:title>The Surgery of Childhood Tumors</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8209c2f92e18cd286b2ee98e027ba2e4"><gtr:id>8209c2f92e18cd286b2ee98e027ba2e4</gtr:id><gtr:otherNames>Tobias E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>978-3-662-48588-0</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFA5D506-55C4-4AA8-81F3-84CBE4A0D428"><gtr:id>FFA5D506-55C4-4AA8-81F3-84CBE4A0D428</gtr:id><gtr:title>Urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation.</gtr:title><gtr:parentPublicationTitle>Metabolomics : Official journal of the Metabolomic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ff76a1247e82bc41f9b6eb2b4dabe73"><gtr:id>5ff76a1247e82bc41f9b6eb2b4dabe73</gtr:id><gtr:otherNames>van der Hooft JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1573-3882</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/795E6330-7141-4153-AA52-AF06DD32F16B"><gtr:id>795E6330-7141-4153-AA52-AF06DD32F16B</gtr:id><gtr:title>Research digest: cardiac biomarkers for risk prediction</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45e1f44a10cacab8ee373d2181cc2ec7"><gtr:id>45e1f44a10cacab8ee373d2181cc2ec7</gtr:id><gtr:otherNames>Preiss D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9DB2113-19D5-4714-8B9D-45828EF0198E"><gtr:id>C9DB2113-19D5-4714-8B9D-45828EF0198E</gtr:id><gtr:title>Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a98687e7c5035ccb72273381ed7ac1c7"><gtr:id>a98687e7c5035ccb72273381ed7ac1c7</gtr:id><gtr:otherNames>Kar SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E291C169-2741-43A4-B616-89B8D328CCB8"><gtr:id>E291C169-2741-43A4-B616-89B8D328CCB8</gtr:id><gtr:title>Novel Genetic Associations and Range of Phenotypes in Children with Disorders of Sex Development and Neurodevelopment: Insights from the Deciphering Developmental Disorders Study.</gtr:title><gtr:parentPublicationTitle>Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb046ce3206a809360012b1ac29539e0"><gtr:id>bb046ce3206a809360012b1ac29539e0</gtr:id><gtr:otherNames>Gazdagh G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1661-5425</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58192D1E-2C6D-4DEE-8FA2-6E603D1019AA"><gtr:id>58192D1E-2C6D-4DEE-8FA2-6E603D1019AA</gtr:id><gtr:title>Urine proteomics in the diagnosis of stable angina.</gtr:title><gtr:parentPublicationTitle>BMC cardiovascular disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82870b6be5ba68d10e6d8aed77c5ac2e"><gtr:id>82870b6be5ba68d10e6d8aed77c5ac2e</gtr:id><gtr:otherNames>Neisius U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2261</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/86B83A12-46FC-4153-AA7A-0B390445DA6A"><gtr:id>86B83A12-46FC-4153-AA7A-0B390445DA6A</gtr:id><gtr:title>Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a761433f7a28faf1978205bca7c23c3d"><gtr:id>a761433f7a28faf1978205bca7c23c3d</gtr:id><gtr:otherNames>Zhu AX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N005813/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>